Synthesis of nitrophenol-triazole hybrids demonstrates significant cholinesterase inhibition in vitro, suggesting therapeutic potential.
This study aimed to synthesize novel nitrophenol-triazole hybrid molecules, investigate their biological activities (cholinesterase inhibition, antioxidant, and anticancer effects), and profile them using computational methods (molecular docking, ADMET). Eight new hybrid compounds were successfully synthesized, and the crystal structures of compounds 10a and 10g were determined by single-crystal X-ray diffraction analysis. Among the obtained compounds, derivative 10e exhibited notable cholinesterase inhibitory activity with high potency and selectivity against acetylcholinesterase (AChE), demonstrating an IC50 value of 1.56 µM. The compounds displayed promising antioxidant capacity, especially in terms of ABTS radical scavenging activity, with IC50 values ranging narrowly from 8.01 µg/mL (10a) to 8.52 µg/mL (10d). In anticancer activity evaluations, compound 10a showed noteworthy cytotoxicity against the Caco-2 cell line with an IC50 value of 1.77 µM. In silico ADMET analyses predicted that most compounds adhere to Lipinski's Rule of Five and possess a favorable profile. Molecular docking studies elucidated the binding interactions, revealing binding energies of - 10.9 kcal/mol for compound 10e with AChE and - 9.1 kcal/mol for compound 10h with BuChE.
No takes yet. Share an insight, caveat, or question.
Onur et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: